THE WHAT? Shiseido has agreed to sell its wholly owned Chinese subsidiary, Shiseido Liyuan Cosmetics, to an investor consortium led by IDG Capital, as part of its strategy to streamline operations and improve profitability in China.
THE DETAILS Shiseido has signed a binding agreement to transfer 100% of Shiseido Liyuan Cosmetics (SLC), which manufactures and markets the Chinese cosmetics brand AUPRES, to a consortium led by private equity firm IDG Capital. Established in 1991 as a joint venture with Beijing Liyuan, SLC has operated the AUPRES brand in China since 1994. Shiseido acquired its former partner’s remaining 35% stake in September 2026, ahead of the joint venture agreement’s expiration. The transaction includes SLC’s Beijing manufacturing facility and production equipment, with IDG-managed funds acquiring 95% and a management partnership taking the remaining 5%. Shiseido will continue providing technical assistance, product development support and selected raw materials during the transition. Financial terms were not disclosed, and completion is expected between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approval.
THE WHY? The divestment reflects Shiseido’s strategy to optimise its Chinese cosmetics portfolio, improve capital efficiency and concentrate investment on priority brands and higher-growth opportunities. For the cosmetics industry, the transaction highlights the ongoing restructuring of multinational manufacturers’ operations in China as companies respond to changing consumer demand, increasing domestic competition and the rapid expansion of e-commerce.
Source: Shiseido
